{"entity":{"type":"insider","cik":"0001290166","url":"/insider/0001290166","json_url":"/insider/0001290166.json","name":"QVT Associates GP LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":202,"n_filings":81,"first":"2009-09-24","last":"2019-06-19","span_basis":"filed_date"},"name_variants":[{"name":"QVT Associates GP LLC","source":"filing","n_filings":81,"first_seen":"2009-09-24","last_seen":"2019-06-19"}],"transactions":[{"id":8114983,"accession":"0000899243-19-017480","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-19-017480","line_url":"/filing/0000899243-19-017480#line-3","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4957.0,"shares_display":"4,957","price_per_share":8.1693,"price_display":"8.17","price_state":"stated","total_value":40495.2201,"total_display":"40,495.22","total_whole":"40,495","shares_owned_after":22860013.0,"shares_owned_after_display":"22,860,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-19","filed_date":"2019-06-19","scope":"insider"},{"id":8114982,"accession":"0000899243-19-017480","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-017480","line_url":"/filing/0000899243-19-017480#line-2","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6706.0,"shares_display":"6,706","price_per_share":8.2107,"price_display":"8.21","price_state":"stated","total_value":55060.9542,"total_display":"55,060.95","total_whole":"55,061","shares_owned_after":22855056.0,"shares_owned_after_display":"22,855,056","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-18","filed_date":"2019-06-19","scope":"insider"},{"id":8114981,"accession":"0000899243-19-017480","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-017480","line_url":"/filing/0000899243-19-017480#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6541.0,"shares_display":"6,541","price_per_share":8.5346,"price_display":"8.53","price_state":"stated","total_value":55824.8186,"total_display":"55,824.82","total_whole":"55,825","shares_owned_after":22848350.0,"shares_owned_after_display":"22,848,350","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-17","filed_date":"2019-06-19","scope":"insider"},{"id":8273378,"accession":"0000899243-19-017094","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-19-017094","line_url":"/filing/0000899243-19-017094#line-3","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7144.0,"shares_display":"7,144","price_per_share":7.9107,"price_display":"7.91","price_state":"stated","total_value":56514.0408,"total_display":"56,514.04","total_whole":"56,514","shares_owned_after":22841809.0,"shares_owned_after_display":"22,841,809","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-14","filed_date":"2019-06-14","scope":"insider"},{"id":8273375,"accession":"0000899243-19-017094","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-017094","line_url":"/filing/0000899243-19-017094#line-2","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7367.0,"shares_display":"7,367","price_per_share":7.9466,"price_display":"7.95","price_state":"stated","total_value":58542.6022,"total_display":"58,542.60","total_whole":"58,543","shares_owned_after":22834665.0,"shares_owned_after_display":"22,834,665","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-13","filed_date":"2019-06-14","scope":"insider"},{"id":8273368,"accession":"0000899243-19-017094","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-017094","line_url":"/filing/0000899243-19-017094#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":8.2992,"price_display":"8.30","price_state":"stated","total_value":62244.0,"total_display":"62,244.00","total_whole":"62,244","shares_owned_after":22827298.0,"shares_owned_after_display":"22,827,298","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-12","filed_date":"2019-06-14","scope":"insider"},{"id":7857752,"accession":"0000899243-19-016511","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-19-016511","line_url":"/filing/0000899243-19-016511#line-3","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7189.0,"shares_display":"7,189","price_per_share":8.5817,"price_display":"8.58","price_state":"stated","total_value":61693.8413,"total_display":"61,693.84","total_whole":"61,694","shares_owned_after":22819798.0,"shares_owned_after_display":"22,819,798","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-11","filed_date":"2019-06-11","scope":"insider"},{"id":7857750,"accession":"0000899243-19-016511","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-016511","line_url":"/filing/0000899243-19-016511#line-2","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":8.3459,"price_display":"8.35","price_state":"stated","total_value":62594.25,"total_display":"62,594.25","total_whole":"62,594","shares_owned_after":22812609.0,"shares_owned_after_display":"22,812,609","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-10","filed_date":"2019-06-11","scope":"insider"},{"id":7857748,"accession":"0000899243-19-016511","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-016511","line_url":"/filing/0000899243-19-016511#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6649.0,"shares_display":"6,649","price_per_share":7.965,"price_display":"7.96","price_state":"stated","total_value":52959.285,"total_display":"52,959.28","total_whole":"52,959","shares_owned_after":22805109.0,"shares_owned_after_display":"22,805,109","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-07","filed_date":"2019-06-11","scope":"insider"},{"id":8050089,"accession":"0000899243-19-015910","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-19-015910","line_url":"/filing/0000899243-19-015910#line-3","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Financial Investment Cayman Ltd.","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7082.0,"shares_display":"7,082","price_per_share":7.9951,"price_display":"8.00","price_state":"stated","total_value":56621.2982,"total_display":"56,621.30","total_whole":"56,621","shares_owned_after":22798460.0,"shares_owned_after_display":"22,798,460","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-06","filed_date":"2019-06-06","scope":"insider"},{"id":8050083,"accession":"0000899243-19-015910","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-015910","line_url":"/filing/0000899243-19-015910#line-2","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Financial Investment Cayman Ltd.","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6540.0,"shares_display":"6,540","price_per_share":8.015,"price_display":"8.02","price_state":"stated","total_value":52418.1,"total_display":"52,418.10","total_whole":"52,418","shares_owned_after":22791378.0,"shares_owned_after_display":"22,791,378","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-05","filed_date":"2019-06-06","scope":"insider"},{"id":8580720,"accession":"0000899243-19-015895","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-015895","line_url":"/filing/0000899243-19-015895#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Fund V LP; QVT Associates GP LLC","owner_display_name":"QVT Fund V LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, $0.000017727 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2424242.0,"shares_display":"2,424,242","price_per_share":8.25,"price_display":"8.25","price_state":"stated","total_value":19999996.5,"total_display":"19,999,996.50","total_whole":"19,999,997","shares_owned_after":40765599.0,"shares_owned_after_display":"40,765,599","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-04","filed_date":"2019-06-06","scope":"insider"},{"id":8050077,"accession":"0000899243-19-015910","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-015910","line_url":"/filing/0000899243-19-015910#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Financial Investment Cayman Ltd.","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":7.5881,"price_display":"7.59","price_state":"stated","total_value":56910.75,"total_display":"56,910.75","total_whole":"56,911","shares_owned_after":22784838.0,"shares_owned_after_display":"22,784,838","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-04","filed_date":"2019-06-06","scope":"insider"},{"id":7966617,"accession":"0000899243-19-015402","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-015402","line_url":"/filing/0000899243-19-015402#line-4","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5424.0,"shares_display":"5,424","price_per_share":7.7092,"price_display":"7.71","price_state":"stated","total_value":41814.7008,"total_display":"41,814.70","total_whole":"41,815","shares_owned_after":22777338.0,"shares_owned_after_display":"22,777,338","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-03","filed_date":"2019-06-03","scope":"insider"},{"id":7966615,"accession":"0000899243-19-015402","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-19-015402","line_url":"/filing/0000899243-19-015402#line-3","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5071.0,"shares_display":"5,071","price_per_share":7.6991,"price_display":"7.70","price_state":"stated","total_value":39042.1361,"total_display":"39,042.14","total_whole":"39,042","shares_owned_after":22771914.0,"shares_owned_after_display":"22,771,914","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-31","filed_date":"2019-06-03","scope":"insider"},{"id":7966613,"accession":"0000899243-19-015402","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-015402","line_url":"/filing/0000899243-19-015402","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7251.0,"shares_display":"7,251","price_per_share":8.011242945800578,"price_display":"8.01","price_state":"stated","total_value":58089.5226,"total_display":"58,089.52","total_whole":"58,090","shares_owned_after":22766543.0,"shares_owned_after_display":"22,766,543","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-30","filed_date":"2019-06-03","scope":"insider","n_lines":2},{"id":7966594,"accession":"0000899243-19-015062","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-19-015062","line_url":"/filing/0000899243-19-015062#line-3","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6882.0,"shares_display":"6,882","price_per_share":7.5535,"price_display":"7.55","price_state":"stated","total_value":51983.187,"total_display":"51,983.19","total_whole":"51,983","shares_owned_after":22759592.0,"shares_owned_after_display":"22,759,592","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-29","filed_date":"2019-05-29","scope":"insider"},{"id":7966592,"accession":"0000899243-19-015062","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-015062","line_url":"/filing/0000899243-19-015062#line-2","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3807.0,"shares_display":"3,807","price_per_share":7.6818,"price_display":"7.68","price_state":"stated","total_value":29244.6126,"total_display":"29,244.61","total_whole":"29,245","shares_owned_after":22752710.0,"shares_owned_after_display":"22,752,710","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-28","filed_date":"2019-05-29","scope":"insider"},{"id":7966589,"accession":"0000899243-19-015062","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-015062","line_url":"/filing/0000899243-19-015062#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3796.0,"shares_display":"3,796","price_per_share":7.7011,"price_display":"7.70","price_state":"stated","total_value":29233.3756,"total_display":"29,233.38","total_whole":"29,233","shares_owned_after":22748903.0,"shares_owned_after_display":"22,748,903","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-24","filed_date":"2019-05-29","scope":"insider"},{"id":8114945,"accession":"0000899243-19-014556","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-19-014556","line_url":"/filing/0000899243-19-014556#line-3","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4802.0,"shares_display":"4,802","price_per_share":7.7576,"price_display":"7.76","price_state":"stated","total_value":37251.9952,"total_display":"37,252.00","total_whole":"37,252","shares_owned_after":22745107.0,"shares_owned_after_display":"22,745,107","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-23","filed_date":"2019-05-23","scope":"insider"},{"id":8114944,"accession":"0000899243-19-014556","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-014556","line_url":"/filing/0000899243-19-014556#line-2","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5033.0,"shares_display":"5,033","price_per_share":8.0584,"price_display":"8.06","price_state":"stated","total_value":40557.9272,"total_display":"40,557.93","total_whole":"40,558","shares_owned_after":22740305.0,"shares_owned_after_display":"22,740,305","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-22","filed_date":"2019-05-23","scope":"insider"},{"id":8114943,"accession":"0000899243-19-014556","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-014556","line_url":"/filing/0000899243-19-014556#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9995.0,"shares_display":"9,995","price_per_share":8.5151,"price_display":"8.52","price_state":"stated","total_value":85108.4245,"total_display":"85,108.42","total_whole":"85,108","shares_owned_after":22735272.0,"shares_owned_after_display":"22,735,272","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-21","filed_date":"2019-05-23","scope":"insider"},{"id":8143634,"accession":"0000899243-19-014214","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-014214","line_url":"/filing/0000899243-19-014214","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":8.0524831,"price_display":"8.05","price_state":"stated","total_value":80524.831,"total_display":"80,524.83","total_whole":"80,525","shares_owned_after":22723562.0,"shares_owned_after_display":"22,723,562","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-20","filed_date":"2019-05-20","scope":"insider","n_lines":2},{"id":8143629,"accession":"0000899243-19-014214","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-014214","line_url":"/filing/0000899243-19-014214#line-2","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6200.0,"shares_display":"6,200","price_per_share":7.3615,"price_display":"7.36","price_state":"stated","total_value":45641.3,"total_display":"45,641.30","total_whole":"45,641","shares_owned_after":22715277.0,"shares_owned_after_display":"22,715,277","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-17","filed_date":"2019-05-20","scope":"insider"},{"id":8143627,"accession":"0000899243-19-014214","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-014214","line_url":"/filing/0000899243-19-014214#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5408.0,"shares_display":"5,408","price_per_share":6.7896,"price_display":"6.79","price_state":"stated","total_value":36718.1568,"total_display":"36,718.16","total_whole":"36,718","shares_owned_after":22709077.0,"shares_owned_after_display":"22,709,077","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-16","filed_date":"2019-05-20","scope":"insider"},{"id":8663987,"accession":"0000899243-19-008356","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-008356","line_url":"/filing/0000899243-19-008356#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Axovant Sciences Ltd.","issuer_ticker":"AXON","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Financial Investment Cayman Ltd.; QVT Associates GP LLC","owner_display_name":"QVT Financial Investment Cayman Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, $0.00001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6666667.0,"shares_display":"6,666,667","price_per_share":1.5,"price_display":"1.50","price_state":"stated","total_value":10000000.5,"total_display":"10,000,000.50","total_whole":"10,000,001","shares_owned_after":105952381.0,"shares_owned_after_display":"105,952,381","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-18","filed_date":"2019-03-19","scope":"insider"},{"id":6474293,"accession":"0000899243-18-031450","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-031450","line_url":"/filing/0000899243-18-031450#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Axovant Sciences Ltd.","issuer_ticker":"AXON","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Offshore Ltd.","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, $0.00001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000000.0,"shares_display":"10,000,000","price_per_share":1.0,"price_display":"1.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":99285714.0,"shares_owned_after_display":"99,285,714","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-12-18","filed_date":"2018-12-20","scope":"insider"},{"id":6812587,"accession":"0000899243-18-026091","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-026091","line_url":"/filing/0000899243-18-026091#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2678571.0,"shares_display":"2,678,571","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":37499994.0,"total_display":"37,499,994.00","total_whole":"37,499,994","shares_owned_after":22703669.0,"shares_owned_after_display":"22,703,669","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-10-01","filed_date":"2018-10-03","scope":"insider"},{"id":6619011,"accession":"0000899243-18-015353","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-015353","line_url":"/filing/0000899243-18-015353#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Axovant Sciences Ltd.","issuer_ticker":"AXON","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, $0.00001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14285714.0,"shares_display":"14,285,714","price_per_share":1.75,"price_display":"1.75","price_state":"stated","total_value":24999999.5,"total_display":"24,999,999.50","total_whole":"25,000,000","shares_owned_after":89285714.0,"shares_owned_after_display":"89,285,714","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-05","filed_date":"2018-06-07","scope":"insider"},{"id":6216703,"accession":"0000899243-18-009452","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-009452","line_url":"/filing/0000899243-18-009452#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, $0.000017727 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1110015.0,"shares_display":"1,110,015","price_per_share":20.27,"price_display":"20.27","price_state":"stated","total_value":22500004.05,"total_display":"22,500,004.05","total_whole":"22,500,004","shares_owned_after":38341357.0,"shares_owned_after_display":"38,341,357","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-04-02","filed_date":"2018-04-04","scope":"insider"},{"id":8456534,"accession":"0001209191-15-003951","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001209191-15-003951","line_url":"/filing/0001209191-15-003951","is_derivative":false,"issuer_cik":"0001098972","issuer_name":"AGENUS INC","issuer_ticker":"AGEN","issuer_name_source":null,"issuer_url":"/issuer/0001098972","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.01 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2343630.0,"shares_display":"2,343,630","price_per_share":5.312835959601132,"price_display":"5.31","price_state":"stated","total_value":12451321.74,"total_display":"12,451,321.74","total_whole":"12,451,322","shares_owned_after":7423440.0,"shares_owned_after_display":"7,423,440","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-01-09","filed_date":"2015-01-13","scope":"insider","n_lines":14},{"id":7034361,"accession":"0001209191-14-042349","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-14-042349","line_url":"/filing/0001209191-14-042349#line-5","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":"0001290166","owner_name":"QVT Associates GP LLC","owner_display_name":"QVT Associates GP LLC","owner_url":"/insider/0001290166","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":944400.0,"shares_display":"944,400","price_per_share":7.71,"price_display":"7.71","price_state":"stated","total_value":7281324.0,"total_display":"7,281,324.00","total_whole":"7,281,324","shares_owned_after":9093153.0,"shares_owned_after_display":"9,093,153","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-06-16","filed_date":"2014-06-18","scope":"insider"},{"id":7034359,"accession":"0001209191-14-042349","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-14-042349","line_url":"/filing/0001209191-14-042349#line-4","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":"0001290166","owner_name":"QVT Associates GP LLC","owner_display_name":"QVT Associates GP LLC","owner_url":"/insider/0001290166","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400751.0,"shares_display":"400,751","price_per_share":7.57,"price_display":"7.57","price_state":"stated","total_value":3033685.07,"total_display":"3,033,685.07","total_whole":"3,033,685","shares_owned_after":10287553.0,"shares_owned_after_display":"10,287,553","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-06-16","filed_date":"2014-06-18","scope":"insider"},{"id":7034357,"accession":"0001209191-14-042349","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-14-042349","line_url":"/filing/0001209191-14-042349#line-3","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":"0001290166","owner_name":"QVT Associates GP LLC","owner_display_name":"QVT Associates GP LLC","owner_url":"/insider/0001290166","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":224400.0,"shares_display":"224,400","price_per_share":7.79,"price_display":"7.79","price_state":"stated","total_value":1748076.0,"total_display":"1,748,076.00","total_whole":"1,748,076","shares_owned_after":8868753.0,"shares_owned_after_display":"8,868,753","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-06-16","filed_date":"2014-06-18","scope":"insider"},{"id":7034354,"accession":"0001209191-14-042349","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-14-042349","line_url":"/filing/0001209191-14-042349#line-2","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":"0001290166","owner_name":"QVT Associates GP LLC","owner_display_name":"QVT Associates GP LLC","owner_url":"/insider/0001290166","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":150000.0,"shares_display":"150,000","price_per_share":7.81,"price_display":"7.81","price_state":"stated","total_value":1171500.0,"total_display":"1,171,500.00","total_whole":"1,171,500","shares_owned_after":10037553.0,"shares_owned_after_display":"10,037,553","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-06-16","filed_date":"2014-06-18","scope":"insider"}],"collapsed":true,"next_cursor":"2014-06-16|7034354","ledger_fault":false,"count":{"value":53,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":17,"open_market":true},{"code":"S","label":"Open-market sale","n":36,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":53},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001740547","name":"Urovant Sciences Ltd.","url":"/issuer/0001740547","role":"Ten percent owner","n_filings":9,"first_seen":"2018-10-03","last_seen":"2019-06-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001679082","name":"Myovant Sciences Ltd.","url":"/issuer/0001679082","role":"Director, Ten percent owner, Other","n_filings":2,"first_seen":"2018-04-04","last_seen":"2019-06-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001636050","name":"Axovant Sciences Ltd.","url":"/issuer/0001636050","role":"Ten percent owner","n_filings":3,"first_seen":"2018-06-07","last_seen":"2019-03-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001098972","name":"AGENUS INC","url":"/issuer/0001098972","role":"Ten percent owner","n_filings":1,"first_seen":"2015-01-13","last_seen":"2015-01-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001070336","name":"ACHILLION PHARMACEUTICALS INC","url":"/issuer/0001070336","role":"Ten percent owner","n_filings":13,"first_seen":"2013-07-05","last_seen":"2014-06-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001367920","name":"CONCERT PHARMACEUTICALS, INC.","url":"/issuer/0001367920","role":"Ten percent owner","n_filings":1,"first_seen":"2014-02-21","last_seen":"2014-02-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001128495","name":"ANADYS PHARMACEUTICALS INC","url":"/issuer/0001128495","role":"Ten percent owner","n_filings":20,"first_seen":"2010-07-06","last_seen":"2011-10-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001274913","name":"INHIBITEX, INC.","url":"/issuer/0001274913","role":"Ten percent owner","n_filings":18,"first_seen":"2009-11-03","last_seen":"2011-09-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001011835","name":"MEDIVATION, INC.","url":"/issuer/0001011835","role":"Ten percent owner","n_filings":10,"first_seen":"2010-09-14","last_seen":"2011-06-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001452217","name":"TPC Group Inc.","url":"/issuer/0001452217","role":"Ten percent owner, Other","n_filings":3,"first_seen":"2010-04-08","last_seen":"2011-01-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001301081","name":"Pharmasset Inc","url":"/issuer/0001301081","role":"Ten percent owner","n_filings":1,"first_seen":"2009-09-24","last_seen":"2009-09-24"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001290166","retrieved_at":"2026-08-23T02:52:29+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}